Loading organizations...
CytoSolv is a biotechnology company based in Providence, Rhode Island, that provides a computational systems biology platform designed to model and predict how various molecular compounds interact within living systems. The infrastructure integrates complex molecular pathways into unified system models, enabling pharmaceutical and biotechnology clients to discover synergistic multiple combination therapeutics across the human, animal, and plant health sectors. Operating through a business model focused on platform licensing and commercialization services, the enterprise received $500,000 in seed funding from the Slater Technology Fund to support its early operations. Evolving from initial systems biology research conducted at MIT over 15 years of development, the organization also advanced specialized cell encapsulation technology that led to an acquisition by Semma Therapeutics. CytoSolv was founded in 2009 by Dr. Shiva Ayyadurai, Dr. Moses Goddard, Christopher Thanos, and John Mills.
CytoSolv has raised $500K across 1 funding round.
CytoSolv has raised $500K in total across 1 funding round.
CytoSolv has raised $500K across 1 funding round. Most recently, it raised $500K Seed in February 2010.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 9, 2010 | $500K Seed | Slater Technology Fund | — | Announced |
CytoSolv has raised $500K in total across 1 funding round.
CytoSolv's investors include Slater Technology Fund.
